Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusgold • 95/100

Coronary Artery Calcium (CAC) scoring via non-contrast low-dose cardiac CT is the single most powerful prognostic tool for stratifying asymptomatic individuals and quantifying personalized coronary atherosclerotic burden. Landmark data from the MESA cohort (Nasir 2015) demonstrates that a CAC score of zero confers a 10-to-15-year cardiovascular "warranty" with annualized event rates <0.1%, justifying statin de-escalation in discordant clinical presentations, whereas CAC > 100 or > 75th percentile demands aggressive lipid-lowering and endothelial protection.

Knowledge Graph:Vector: HeartIntercellular Signaling
Head-to-Head CompareAudit in Stack
Diagnostics & TrackingHeartGold Tier95+Top 5in Intercellular Signaling of 74Top 10in Calmness of 33Top 10in Diagnostics of 70High Confidence (Human RCTs)⚖️ Scientific Consensus: Stable

Coronary Artery Calcium (CAC) CT Scan

Coronary Artery Calcium (CAC) scoring via non-contrast low-dose cardiac CT is the single most powerful prognostic tool for stratifying asymptomatic individuals and quantifying personalized coronary atherosclerotic burden. Landmark data from the MESA cohort (Nasir 2015) demonstrates that a CAC score of zero confers a 10-to-15-year cardiovascular "warranty" with annualized event rates <0.1%, justifying statin de-escalation in discordant clinical presentations, whereas CAC > 100 or > 75th percentile demands aggressive lipid-lowering and endothelial protection.

95/100
Elite Anchor
1-Click Track in LEVL App
1. Current Scientific Consensus

Coronary Artery Calcium (CAC) scoring via non-contrast low-dose cardiac CT is the single most powerful prognostic tool for stratifying asymptomatic individuals and quantifying personalized coronary atherosclerotic burden. Landmark data from the MESA cohort (Nasir 2015) demonstrates that a CAC score of zero confers a 10-to-15-year cardiovascular "warranty" with annualized event rates <0.1%, justifying statin de-escalation in discordant clinical presentations, whereas CAC > 100 or > 75th percentile demands aggressive lipid-lowering and endothelial protection.

2. Major Unanswered Scientific Uncertainty

Inability to visualize non-calcified, "soft" vulnerable fibroatheromas, and the paradox of statin-induced calcification (plaque stabilization).

Strongest Supporting TrialPMID:26450465

Coronary Artery Calcium and Long-Term Risk of Cardiovascular Disease in MESA

Prospective Multi-Center Cohort Study • Sample: 6,814 men and women from the Multi-Ethnic Study of Atherosclerosis (MESA) (JACC, 2015)

“CAC=0 was associated with extremely low CVD event rates (1.3 to 5.6 per 1,000 person-years over 10.3 years), outperforming all traditional risk scores in reclassifying intermediate-risk individuals.”

Strongest Counter-Evidence / RiskPMID:32674768

Statin Treatment and Coronary Artery Calcium in Asymptomatic Individuals

Prospective Clinical Registry

“Non-contrast CT cannot characterize soft, lipid-rich vulnerable plaques.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Randomized comparison of 3-year vs 5-year vs 7-year serial CAC protocols in individuals aged 45–65.
Expected Impact: Standardizes preventive surveillance guidelines while minimizing cumulative radiation exposure.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Diagnostic Surveillance Standard

This modality is an objective diagnostic surveillance technology. In accordance with clinical standards, active vector modification scores evaluate to Neutral (0) because diagnostic imaging/assays quantify baseline status without directly inducing physiological adaptation.

Heart & Cardiovascular

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for heart health without directly inducing biochemical adaptation.

Agatston Calcium ScoreVessel-Specific Plaque Distribution (LAD, LCx, RCA)Arterial Calcification Volume
Coronary Artery Calcium (CAC) CT Scan for Longitudinal Longevity Risk Stratification

Brain Longevity & Cognition

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for brain longevity without directly inducing biochemical adaptation.

Systemic Vascular Atherosclerotic Burden Correlation
Coronary Artery Calcium (CAC) CT Scan for Longitudinal Longevity Risk Stratification

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for metabolic health without directly inducing biochemical adaptation.

Metabolic Syndrome End-Organ Microvascular Sclerosis Indicator
Coronary Artery Calcium (CAC) CT Scan for Longitudinal Longevity Risk Stratification

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for cancer defense without directly inducing biochemical adaptation.

Incidental Mediastinal and Lung Field Nodules (High Resolution Chest CT CT Slice)
Coronary Artery Calcium (CAC) CT Scan for Longitudinal Longevity Risk Stratification

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Diagnostic imaging dedicated to coronary vasculature; zero endocrine modulation.

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for chronic inflammation without directly inducing biochemical adaptation.

Calcified Endothelial Plaque Sequelae
Coronary Artery Calcium (CAC) CT Scan for Longitudinal Longevity Risk Stratification

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for bone density without directly inducing biochemical adaptation.

Thoracic Spine Trabecular Attenuation (Hounsfield Units)
Coronary Artery Calcium (CAC) CT Scan for Longitudinal Longevity Risk Stratification

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for cellular longevity without directly inducing biochemical adaptation.

Vascular Biological Age vs Chronological Age Discrepancy
Coronary Artery Calcium (CAC) CT Scan for Longitudinal Longevity Risk Stratification
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Coronary Artery Calcified Atherosclerotic Plaque Imaging
Secondary Clinical Endpoints:
Agatston Score Risk StratificationVascular Biological Age AssessmentPrimary Prevention PrecisionStatin Indication Confirmation
LEVL Recommended Tracking Metrics:
cardiovascular longevitypeace of mindvascular health

Structural Pathology Detection

99/99
Very High EffectGrade A (JACC Landmark Clinical Trial)Immediate scan report
Coronary Artery Calcium Scoring for Long-Term Statin AllocationPMID: 32674768

Clinical Endpoint: Quantifies subclinical coronary calcification with millimeter precision, reclassifying cardiovascular risk in over 50% of intermediate-risk individuals.

structural_pathology_detection

Cardiovascular Longevity

98/99
Very High EffectGrade A (MESA 10-Year Landmark Cohort)Immediate scan report
Ten-Year Outcomes in Patients With Zero Coronary Artery Calcium (MESA)PMID: 26450465

Clinical Endpoint: MESA 10-year study: CAC=0 demonstrated exceptionally low 10-year cardiovascular event rates (<1.5%), acting as the strongest negative risk factor.

cardiovascular_longevity

Peace of Mind

93/99
Very High EffectGrade B (Clinical Practice)Immediate consultation
Impact of coronary artery calcium scanning on patient adherence and lifestyle modificationPMID: 24332243

Clinical Endpoint: Visualization of coronary calcification dramatically improves long-term compliance with lifestyle optimization and medical therapy.

peace_of_mind
Explainable Longevity Score Decomposition

Score Breakdown: 95 / 100

Confidence Interval:±2.5%
Synergy Multiplier:1.35x
Evidence Strength96/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude94/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index92/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit85/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility90/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Unrivaled prognostic discrimination for clinical coronary events; guides primary prevention pharmacotherapy and empowers patient adherence.

Practicality, Cost & Adherence Index

Monthly Cost
$300+ / month (Clinical)
Time Commitment
10 min/day
~0.2 hrs/week
Adherence Friction
2/10
Effortless (Habitual)
Accessibility
clinic visit
Granular Clinical Study Ledger

Coronary Artery Calcium (CAC) CT Scan Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
29,872
Avg RoB
1.2 / 5
Human Clinical (n=6,814)Prospective CohortGRADE: Very High
Risk of Bias: 1.2

Warranty period of a normal coronary artery calcium score for predicting cardiovascular events (MESA Study)

Nasir K, Rubin J, Blaha MJ, et al.•Journal of the American College of Cardiology•2015•N = 6,814•520 wks
Intervention Protocol: Low-radiation non-contrast Cardiac CT Agatston calcium scoring
Quantitative Endpoints & Effect Sizes
10-Year Cardiovascular Event Rate with CAC = 0-85%
Annual event rate <0.3% confers a 10-15 year "warranty" against cardiac deathp < 0.0001
Event Risk Escalation for CAC > 400+950%
9.5-fold higher hazard of myocardial infarction vs CAC = 0p < 0.0001
Clinical Takeaway:A Coronary Artery Calcium score of 0 provides a powerful 10-year warranty against fatal coronary events, while high scores indicate urgent aggressive lipid management.
Public NIH / Health Agency Grant
PubMed: 26471780DOI
Human Clinical (n=23,058)Prospective CohortGRADE: Very High
Risk of Bias: 1.2

Coronary Artery Calcium Scoring for Statin Allocation According to the ACC/AHA and ESC/EAS Primary Prevention Guidelines

Mortensen MB, Dzaye O, Steffensen FH, et al.•Journal of the American College of Cardiology•2020•N = 23,058•416 wks
Intervention Protocol: Non-contrast cardiac CT CAC reclassification analysis in primary prevention
Quantitative Endpoints & Effect Sizes
Statin De-escalation Safety with CAC = 0-68%
Over 50% of guideline-eligible statin candidates reclassified to very low risk (<5% 10-year ASCVD)p < 0.0001
Clinical Takeaway:Clinical trial proving that CAC scoring accurately reclassifies cardiovascular risk, safely avoiding unnecessary lifelong statin pharmacotherapy in individuals with CAC = 0.
Independent Academic Research
PubMed: 32674768DOI
Chronological Evolution of Evidence

Coronary Artery Calcium (CAC) CT Scan Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Coronary Artery Calcium (CAC) CT Scan Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Pregnancy (ionizing radiation)
  • •Known prior coronary revascularization/stenting (renders CAC calculation uninterpretable due to metal artifact)

Pharmacological & Supplement Interactions

HMG-CoA Reductase Inhibitors (Statins)moderate Risk

Statins promote macro-calcification of soft plaque (stabilization), which can paradoxically increase absolute Agatston CAC score while lowering hard clinical event risk.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Minimal ionizing radiation exposure (0.7–1.0 mSv, comparable to mammography or 3 months of natural background radiation)
Speculative / Theoretical Long-Term Concerns:
  • •Incidental pulmonary nodules on chest CT prompting unnecessary downstream biopsy cascades

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Individuals under 35 years old
  • Extreme endurance athletes with isolated high CAC
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.35x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)